Advertisement
Advertisement
U.S. markets closed
S&P Futures
3,930.25 +30.75 (+0.79%) Dow Futures
31,410.00 +197.00 (+0.63%) Nasdaq Futures
11,950.50 +109.75 (+0.93%) Russell 2000 Futures
1,786.70 +14.50 (+0.82%) Crude Oil
109.92 -0.36 (-0.33%) Gold
1,848.30 +6.20 (+0.34%)
Ocular Therapeutix, Inc. (OCUL)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 3.4000 |
| Open | 3.4600 |
| Bid | 3.0000 x 1000 |
| Ask | 3.9400 x 2200 |
| Day's Range | 3.2350 - 3.5000 |
| 52 Week Range | 2.9650 - 15.3160 |
| Volume | |
| Avg. Volume | 663,440 |
| Market Cap | 257.145M |
| Beta (5Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0170 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.71 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for OCUL
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Ocular Therapeutix, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.RatingFair ValueEconomic Moat4 months agoMorningstar
- Simply Wall St.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Just Slashed This Year's Revenue Estimates By 20%
Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...
- Zacks
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
BEDFORD, Mass., May 09, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
